Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline  Sander C.J.

Slides:



Advertisements
Similar presentations
Sven Haller Haller, Nguyen, Rodriguez, Emch, Gold, Bartsch, Lovblad, Giannakopoulos.
Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Sleep disruption changes across the disease trajectory: Pilot findings from the healthy patterns sleep study Nancy A. Hodgson, Albert J. Safi Alzheimer's.
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Middle age self-report risk score predicts cognitive functioning and dementia in 20– 40 years  Eero Vuoksimaa, Juha O. Rinne, Noora Lindgren, Kauko Heikkilä,
Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment  Lies Clerx, Ineke A. van.
Volume 3, Issue 4, Pages (November 2017)
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study  Wesley.
Manuela Tondelli, Gordon K. Wilcock, Paolo Nichelli, Celeste A
Volume 3, Issue 1, Pages 1-9 (January 2017)
Ellemarije Altena, Hugo Vrenken, Ysbrand D. Van Der Werf, Odile A
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease  Hlin Kvartsberg, Flora.
Volume 3, Issue 2, Pages (June 2017)
Flora H. Duits, Niels D. Prins, Afina W. Lemstra, Yolande A. L
Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample  Marie Eckerström,
Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease  Valérie.
Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study - DOI: / Fig. 1.
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints  Argonde C. van Harten, Pieter Jelle Visser,
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design  Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.
Joana R. Guedes, Isabel Santana, Catarina Cunha, Diana Duro, Maria R
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
A NOVEL NEUROIMAGING APPROACH TO CAPTURE COGNITIVE RESERVE
Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire  Roos J.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease  Valentina Escott-Price, Maryam Shoai, Richard Pither, Julie.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Volume 3, Issue 2, Pages (June 2017)
Volume 5, Pages (December 2016)
Multidimensional assessment of challenging behaviors in advanced stages of dementia in nursing homes—The insideDEM framework  Stefan Teipel, Christina.
Alzheimer’s disease core biomarkers and prediction of dementia in MCI: The effect of age at onset  Anna Caroli, Samantha Galluzzi, Clarissa Ferrari, Annapaola.
An amylin analog used as a challenge test for Alzheimer's disease
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission.
DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS  Teemu Paajanen, Shadi Mahdiani, Marie.
Colin Groot, Chris W. J. van der Weijden, Wiesje M
Volume 2, Issue 1, Pages (January 2016)
Volume 3, Issue 1, Pages (January 2017)
Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang 
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin  Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,
Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States.
The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: A longitudinal case report  Carolin A.M. Koriath,
Early Dementia Distinguishing AD From MCI
Alzheimer's disease drug development pipeline: 2018
Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics  Y.H. van Beurden, S. Nezami,
S. Imindu Liyanage, Clarissa Santos, Donald F. Weaver 
Fusion of deep learning models of MRI scans, Mini–Mental State Examination, and logical memory test enhances diagnosis of mild cognitive impairment  Shangran.
Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W
Appendectomy is followed by increased risk of Crohn's disease
Extrafrontal structural changes in juvenile myoclonic epilepsy: A topographic analysis of combined structural and microstructural brain imaging  Seong.
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
A.H. Gifford  Journal of Cystic Fibrosis 
Baseline Characteristics of the Subjects
International Journal of Cardiology
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression  Corline Brouwers, Stefan.
The atypical pneumonias: clinical diagnosis and importance
Evaluation of diagnostic tests
Error processing in patients with Alzheimer's disease
Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective  Matthew Baumgart, Heather M. Snyder,
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS  Betty M. Tijms, Mara ten Kate, Sander C.J.
Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.
Clinical and Translational Radiation Oncology
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Presentation transcript:

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline  Sander C.J. Verfaillie, Betty Tijms, Adriaan Versteeg, Marije R. Benedictus, Femke H. Bouwman, Philip Scheltens, Frederik Barkhof, Hugo Vrenken, Wiesje M. van der Flier  Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring  Volume 5, Pages 43-52 (January 2016) DOI: 10.1016/j.dadm.2016.10.007 Copyright © 2016 The Authors Terms and Conditions

Fig. 1 Kaplan-Meier curves of the AD-signature cortical thickness (A) and medial temporal cortical thickness (B) in relation to clinical progression to MCI or dementia. Abbreviations: AD, Alzheimer's disease; CP, clinical progression. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2016 5, 43-52DOI: (10.1016/j.dadm.2016.10.007) Copyright © 2016 The Authors Terms and Conditions

Fig. 2 Vertex-wise analyses of cortical thickness between SCD patients with and without clinical progression to MCI or dementia superimposed on an average pail surface. Red reflects thinner cortex, whereas blue reflects thicker cortex at baseline in SCD patients with clinical progression compared with patients without clinical progression. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2016 5, 43-52DOI: (10.1016/j.dadm.2016.10.007) Copyright © 2016 The Authors Terms and Conditions